Inidascamine (RL-007)
Unknown / undisclosed
Evidence outlook
Cognitive Impairment Associated with Schizophrenia: topline reported 2025-07-25
The sponsor reported topline results on 2025-07-25 (Phase 2b CIAS topline: inidascamine missed the primary endpoint). The announcement is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05686239 NCT05686239 · Schizophrenia Registry: NCT05686239 | 2 | MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite (6 weeks) 2025-04-09 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
NCT04822883 NCT04822883 · Schizophrenia Registry: NCT04822883 | 2 | Incidence of Treatment-emergent Adverse Events (TEAE) (Study Day 8.); Change in blood pressure (systolic and diastolic) from baseline (Study Day 4); Change in heart rate from baseline (Study Day 4); Change in respiratory rate from baseline (Study Day 4); Change in temperature from baseline (Study Day 4); Change in electrocardiogram (ECG) from baseline (Study Day 3); Change in the Columbia Suicide Severity Rating Scale (C-SSRS) from baseline (Study Day 8) 2021-10-28 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Cognitive Impairment Associated with Schizophrenia: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Inidascamine (RL-007): this drug | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| ALTO-101 | Phase 2(overall) | Small molecule | PDE4 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent